HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
[Shanghai, Taipei, and San Francisco | January 26, 2026] —— HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
HanchorBio Chairman Scott Liu (left) and WuXi Biologics CEO Chris Chen (right) at the signing ceremony of strategic partnership.
Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development and manufacturing of HanchorBio’s innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.
This partnership reflects HanchorBio’s strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics’ proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.
WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, WuXi Biologics’ integrated platform supports 945 projects, approximately 60% of which involve bi- and multi-specific antibodies, ADCs, and fusion proteins, underscoring its strong track record in accelerating the development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite targeted integration (TI)-based CHO cell line platform and WuXiHighTM high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.
For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.
Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: “This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline.”
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: ” We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics’ comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi fusion proteins and help bring transformative therapies to patients worldwide.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技（TPEx：7827）與全球領先的合同研究、開發和生產（CRDMO）服務公司藥明生物（WuXi Biologics, 2269.HK）共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技研發管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
根據協定，藥明生物將提供一站式的生物藥開發與生產服務，涵蓋細胞株開發、工藝與生物分析方法開發、製劑開發及GMP生產。此次合作旨在加速臨床轉譯、增強CMC執行效率，並支援漢康生技基於FBDB™平臺技術所研發出的創新融合蛋白藥，來擴展其全球開發與生產。
此次合作體現了漢康生技推進平臺衍生、多資產管線的戰略，即從早期臨床階段到商業化全程注重開發速度、生產穩健性與資本效率。透過借助藥明生物在複雜生物藥領域已驗證的能力及其全球品質體系，漢康生技致力於縮短開發週期，並在多個臨床項目中保持運營靈活性。
藥明生物在雙特異性/多特異性抗體、抗體藥物複合體藥物（ADC）及融合蛋白等複雜生物藥領域擁有豐富經驗。截至2025年，藥明生物CRDMO一站式平臺承載著945個項目，其中近60%為雙特異性/多特異性抗體、ADC及融合蛋白項目，這充分印證了其在加速先進療法開發與生產方面的可靠實力。公司擁有的專有技術平臺，如基於定點整合（TI）技術的CHO細胞株平臺WuXia™ TrueSite，以及高通量製劑開發平臺WuXiHigh™，均旨在提升開發速度、產品品質與高效規模化生產。
此次合作將有力推動漢康生技專有的FBDB™技術平臺的持續拓展。該平臺能夠實現多功能融合蛋白的工程化設計，以協同調節先天性與適應性免疫。此次合作代表漢康生技在推動前沿研發創新與產業化落地深度融合上取得重要進展，為其腫瘤及自體免疫疾病管線的全球臨床開發提供強力的支撐。
漢康生技創辦人、董事長兼執行長劉世高博士表示，與藥明生物的合作將增強漢康生技將平臺驅動的創新轉化為高品質臨床與商業資產的能力。在推進多款新一代融合蛋白專案時，執行速度、生產可靠性與規模化能力至關重要。藥明生物在複雜生物藥及全球開發領域已獲驗證的專業經驗，使其成為漢康生技構建差異化、多資產免疫治療管線的強大戰略合作夥伴。
藥明生物執行長陳智勝博士也指出，藥明生物非常高興與漢康生技開啟此次合作，這充分體現了客戶對藥明生物在新一代生物藥，特別是複雜生物藥開發能力的高度信任。憑藉藥明生物行業領先的技術平臺、成熟的專業經驗以及對品質的不懈追求，藥明生物致力於加速漢康生技創新型雙/多功能融合蛋白藥物的開發，將創新型療法更快地帶給全球患者。
關於漢康生技
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康生技”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDBTM多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康生技的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。
關於藥明生物
藥明生物（股票代碼：2269.HK）是一家全球領先的合同研究、開發和生產（CRDMO）公司。公司通過開放式、一站式生物製藥能力和技術賦能平臺，提供全方位的端到端服務，說明合作夥伴發現、開發及生產生物藥，實現從概念到商業化生產的過程，加速全球生物藥研發進程，降低研發成本，造福病患。
藥明生物在中國大陸、美國、愛爾蘭、德國、新加坡和卡達擁有超過12,000名員工。通過藥明生物的專業服務團隊，以及先進技術和精深洞見，公司為客戶提供高效經濟的生物藥解決方案。截至2025年12月底，藥明生物説明客戶研發和生產的綜合專案高達945個，其中包括74個臨床III期項目，25個商業化生產項目。
藥明生物以可持續發展為長期業務增長的基石。公司持續推動綠色創新技術，為全球合作夥伴提供先進的端到端綠色CRDMO解決方案，同時在ESG方面不斷取得卓越成就。秉承創造共用價值的理念，公司攜手利益相關方構建可持續發展生態，通過負責任運營模式推動社會價值與生態效益雙提升，實現全價值鏈的協同賦能。